Skip to main content
. 2018 Jun 14;8(2):130–139. doi: 10.1159/000489505

Table 1.

Characteristics of the trials used in this study

Trials 24
Arms in each trial  
 2 22
 3 2
Phase of trial  
 Phase III 14
 Randomized phase II 10
Publication status  
 Published 19
 Unpublished 5
Treatment line  
 First 16
 Second 8
Control arm  
 Placebo 12
 Doxorubicin 2
 Sorafenib 10
Arms 50
Patients in each arm  
 Median 134.5
 Range 19–578